On April 17, 2024, TORL Biotherapeutics LLC closed the transaction. The company has received a $300,000 in its second and final tranche, bringing total funding to $158,300,000 in the transaction. The transaction included participation from 52 investors pursuant to exemption provided under Regulation D.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
43.36 USD | -1.52% | -3.77% | -15.49% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-15.49% | 87.9B | |
+34.35% | 705B | |
+29.39% | 583B | |
-3.49% | 364B | |
+20.15% | 332B | |
+6.19% | 291B | |
+14.11% | 238B | |
-3.03% | 210B | |
+10.02% | 209B | |
+9.21% | 169B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- TORL BioTherapeutics LLC announced that it has received $158.3 million in funding from a group of investors